Jessica Carmen, Ph.D., U.S. Business Development Advisor
Oct. 12 | 11:15am | AVROBIO Ballroom
Oxford, United Kingdom
Using our unique LentiVector® delivery platform, Oxford Biomedica has created a valuable portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, and CNS disorders. We have strong partnerships with Novartis, Bioverativ (part of the Sanofi Group), Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations, Immune Design, and Orchard Therapeutics, providing them with access to our intellectual property, state-of-the-art production facilities, and expertise. In addition, we have licensed products and technology rights to Boehringer Ingelheim, Sanofi, and Axovant. These partnerships provide us with multiple income streams, consisting of upfront milestone payments, development and production fees, and potential royalties on future product sales. We plan to progress our wholly-owned products via spin-outs and out-licensing opportunities, while continuing to invest in our LentiVector® platform. We plan to continue our preclinical R&D to discover new potential products.